[시장보고서]세계의 다낭성난소증후군(PCOS) 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)

세계의 다낭성난소증후군(PCOS) 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)

Polycystic Ovarian Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

상품코드 : 1552647

리서치사 : Transparency Market Research

발행일 : 2024년 07월

페이지 정보 : 영문 178 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,372,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 12,707,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 17,041,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

다낭성난소증후군(PCOS) 치료제 시장 - 조사 범위

TMR의 조사 보고서 "다낭성 난소 증후군(PCOS) 치료 세계 시장"은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측 연도로 하여 2018년부터 2034년까지 세계 다낭성난소증후군(PCOS) 치료 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 다낭성난소증후군(PCOS) 치료 시장의 연평균 복합 성장률(CAGR%)도 제시합니다.

이 보고서는 광범위한 1차 조사, KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체와의 인터뷰, 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참조하여 다낭성난소증후군 치료제 시장을 추론하기 위한 2차 조사를 통해 작성되었습니다. 낭포성 난소 증후군(PCOS) 치료 시장을 추론했습니다.

시장 현황
2023년 시장 규모	27억 달러
2034년 시장 규모	43억 달러
CAGR	4.6%

이 보고서는 세계 다낭성 난소 증후군(PCOS) 치료 시장의 경쟁 환경을 조사했습니다. 세계 다낭성난소증후군(PCOS) 치료제 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되었습니다. 기업 개요, 재무 상태, 최근 동향, SWOT 등 세계 다낭성 난소 증후군(PCOS) 치료 시장에서 활동하는 주요 업체들이 이 보고서에 소개되어 있습니다.

시장 기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
시장 점유율 분석 : 기업별(2023년)
기업 개요
- Abbott Laboratories
- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb Company
- Ferring B.V.
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
- Laurus Labs
- Zydus Pharmaceuticals(USA) Inc.

LSH

영문 목차

영문목차

Polycystic Ovarian Syndrome Treatment Market - Scope of Report

TMR's report on the global polycystic ovarian syndrome treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global polycystic ovarian syndrome treatment market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global polycystic ovarian syndrome treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the polycystic ovarian syndrome treatment market.

Market Snapshot
Market Value in 2023	US$ 2.7 Bn
Market Value in 2034	US$ 4.3 Bn
CAGR	4.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global polycystic ovarian syndrome treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global polycystic ovarian syndrome treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global polycystic ovarian syndrome treatment market.

The report delves into the competitive landscape of the global polycystic ovarian syndrome treatment market. Key players operating in the global polycystic ovarian syndrome treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global polycystic ovarian syndrome treatment market profiled in this report.

Key Questions Answered in Global polycystic ovarian syndrome treatment Market Report:

What is the sales/revenue generated by polycystic ovarian syndrome treatment across all regions during the forecast period?
What are the opportunities in the global polycystic ovarian syndrome treatment market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Polycystic Ovarian Syndrome Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global polycystic ovarian syndrome treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global polycystic ovarian syndrome treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global polycystic ovarian syndrome treatment market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Polycystic Ovarian Syndrome Treatment Market

4. Market Overview

4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast, 2020-2034

5. Key Insights

5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2020-2034
- 6.3.1. Oral Contraceptives
- 6.3.2. Antiandrogens
- 6.3.3. Insulin-sensitizing Agent
- 6.3.4. Antidepressant
- 6.3.5. Anti-obesity
- 6.3.6. Diuretics
- 6.3.7. Others
6.4. Market Attractiveness Analysis, by Drug Class

7. Global Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast, by Distribution Channel

7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2020-2034
- 7.3.1. Hospital Pharmacies
- 7.3.2. Retail Pharmacies
- 7.3.3. Online Pharmacies
7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast, by Region

8.1. Key Findings
8.2. Market Value Forecast, by Region, 2020-2034
- 8.2.1. North America
- 8.2.2. Europe
- 8.2.3. Asia Pacific
- 8.2.4. Latin America
- 8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region

9. North America Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast

9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Drug Class, 2020-2034
- 9.3.1. Oral Contraceptives
- 9.3.2. Antiandrogens
- 9.3.3. Insulin-sensitizing Agent
- 9.3.4. Antidepressant
- 9.3.5. Anti-obesity
- 9.3.6. Diuretics
- 9.3.7. Others
9.4. Market Value Forecast, by Distribution Channel, 2020-2034
- 9.4.1. Hospital Pharmacies
- 9.4.2. Retail Pharmacies
- 9.4.3. Online Pharmacies
9.5. Market Value Forecast, by Country, 2020-2034
- 9.5.1. U.S.
- 9.5.2. Canada
9.6. Market Attractiveness Analysis
- 9.6.1. By Drug Class
- 9.6.2. By Distribution Channel
- 9.6.3. By Country

10. Europe Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast

10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2020-2034
- 10.3.1. Oral Contraceptives
- 10.3.2. Antiandrogens
- 10.3.3. Insulin-sensitizing Agent
- 10.3.4. Antidepressant
- 10.3.5. Anti-obesity
- 10.3.6. Diuretics
- 10.3.7. Others
10.4. Market Value Forecast, by Distribution Channel, 2020-2034
- 10.4.1. Hospital Pharmacies
- 10.4.2. Retail Pharmacies
- 10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
- 10.5.1. Germany
- 10.5.2. U.K.
- 10.5.3. France
- 10.5.4. Italy
- 10.5.5. Spain
- 10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
- 10.6.1. By Drug Class
- 10.6.2. By Distribution Channel
- 10.6.3. By Country/Sub-region

11. Asia Pacific Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast

11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2020-2034
- 11.3.1. Oral Contraceptives
- 11.3.2. Antiandrogens
- 11.3.3. Insulin-sensitizing Agent
- 11.3.4. Antidepressant
- 11.3.5. Anti-obesity
- 11.3.6. Diuretics
- 11.3.7. Others
11.4. Market Value Forecast, by Distribution Channel, 2020-2034
- 11.4.1. Hospital Pharmacies
- 11.4.2. Retail Pharmacies
- 11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
- 11.5.1. China
- 11.5.2. Japan
- 11.5.3. India
- 11.5.4. Australia & New Zealand
- 11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
- 11.6.1. By Drug Class
- 11.6.2. By Distribution Channel
- 11.6.3. By Country/Sub-region

12. Latin America Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast

12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2020-2034
- 12.3.1. Oral Contraceptives
- 12.3.2. Antiandrogens
- 12.3.3. Insulin-sensitizing Agent
- 12.3.4. Antidepressant
- 12.3.5. Anti-obesity
- 12.3.6. Diuretics
- 12.3.7. Others
12.4. Market Value Forecast, by Distribution Channel, 2020-2034
- 12.4.1. Hospital Pharmacies
- 12.4.2. Retail Pharmacies
- 12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
- 12.5.1. Brazil
- 12.5.2. Mexico
- 12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
- 12.6.1. By Drug Class
- 12.6.2. By Distribution Channel
- 12.6.3. By Country/Sub-region

13. Middle East & Africa Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast

13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2020-2034
- 13.3.1. Oral Contraceptives
- 13.3.2. Antiandrogens
- 13.3.3. Insulin-sensitizing Agent
- 13.3.4. Antidepressant
- 13.3.5. Anti-obesity
- 13.3.6. Diuretics
- 13.3.7. Others
13.4. Market Value Forecast, by Distribution Channel, 2020-2034
- 13.4.1. Hospital Pharmacies
- 13.4.2. Retail Pharmacies
- 13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
- 13.5.1. GCC Countries
- 13.5.2. South Africa
- 13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
- 13.6.1. By Drug Class
- 13.6.2. By Distribution Channel
- 13.6.3. By Country/Sub-region

14. Competition Landscape

14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2023)
14.3. Company Profiles
- 14.3.1. Abbott Laboratories
  - 14.3.1.1. Company Overview
  - 14.3.1.2. Product Portfolio
  - 14.3.1.3. SWOT Analysis
  - 14.3.1.4. Financial Overview
  - 14.3.1.5. Strategic Overview
- 14.3.2. AstraZeneca plc
  - 14.3.2.1. Company Overview
  - 14.3.2.2. Product Portfolio
  - 14.3.2.3. SWOT Analysis
  - 14.3.2.4. Financial Overview
  - 14.3.2.5. Strategic Overview
- 14.3.3. Bayer AG
  - 14.3.3.1. Company Overview
  - 14.3.3.2. Product Portfolio
  - 14.3.3.3. SWOT Analysis
  - 14.3.3.4. Financial Overview
  - 14.3.3.5. Strategic Overview
- 14.3.4. Bristol-Myers Squibb Company
  - 14.3.4.1. Company Overview
  - 14.3.4.2. Product Portfolio
  - 14.3.4.3. SWOT Analysis
  - 14.3.4.4. Financial Overview
  - 14.3.4.5. Strategic Overview
- 14.3.5. Ferring B.V.
  - 14.3.5.1. Company Overview
  - 14.3.5.2. Product Portfolio
  - 14.3.5.3. SWOT Analysis
  - 14.3.5.4. Financial Overview
  - 14.3.5.5. Strategic Overview
- 14.3.6. Merck KGaA
  - 14.3.6.1. Company Overview
  - 14.3.6.2. Product Portfolio
  - 14.3.6.3. SWOT Analysis
  - 14.3.6.4. Financial Overview
  - 14.3.6.5. Strategic Overview
- 14.3.7. Novartis AG
  - 14.3.7.1. Company Overview
  - 14.3.7.2. Product Portfolio
  - 14.3.7.3. SWOT Analysis
  - 14.3.7.4. Financial Overview
  - 14.3.7.5. Strategic Overview
- 14.3.8. Pfizer Inc.
  - 14.3.8.1. Company Overview
  - 14.3.8.2. Product Portfolio
  - 14.3.8.3. SWOT Analysis
  - 14.3.8.4. Financial Overview
  - 14.3.8.5. Strategic Overview
- 14.3.9. Sanofi S.A.
  - 14.3.9.1. Company Overview
  - 14.3.9.2. Product Portfolio
  - 14.3.9.3. SWOT Analysis
  - 14.3.9.4. Financial Overview
  - 14.3.9.5. Strategic Overview
- 14.3.10. Teva Pharmaceutical Industries Ltd.
  - 14.3.10.1. Company Overview
  - 14.3.10.2. Product Portfolio
  - 14.3.10.3. SWOT Analysis
  - 14.3.10.4. Financial Overview
  - 14.3.10.5. Strategic Overview
- 14.3.11. Amneal Pharmaceuticals, Inc.
  - 14.3.11.1. Company Overview
  - 14.3.11.2. Product Portfolio
  - 14.3.11.3. SWOT Analysis
  - 14.3.11.4. Financial Overview
  - 14.3.11.5. Strategic Overview
- 14.3.12. Laurus Labs
  - 14.3.12.1. Company Overview
  - 14.3.12.2. Product Portfolio
  - 14.3.12.3. SWOT Analysis
  - 14.3.12.4. Financial Overview
  - 14.3.12.5. Strategic Overview
- 14.3.13. Zydus Pharmaceuticals (USA) Inc.
  - 14.3.13.1. Company Overview
  - 14.3.13.2. Product Portfolio
  - 14.3.13.3. SWOT Analysis
  - 14.3.13.4. Financial Overview
  - 14.3.13.5. Strategic Overview

한글목차

다낭성난소증후군(PCOS) 치료제 시장 - 조사 범위

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

제5장 주요 인사이트

제6장 세계 시장 분석과 예측 : 약제 클래스별

제7장 세계 시장 분석과 예측 : 유통 채널별

제8장 세계 시장 분석과 예측 : 지역별

제9장 북미 시장 분석과 예측

제10장 유럽 시장 분석과 예측

제11장 아시아태평양 시장 분석과 예측

제12장 라틴아메리카 시장 분석과 예측

제13장 중동 및 아프리카 시장 분석과 예측

제14장 경쟁 구도